BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients Favorable safety profile of resorbable breast scaffolds in one-year follow-upNo major scaffold-related complications or scaffold removals BellaSeno will initiate multicenter pivotal clinical trial...

BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs Further expansion of management expertise to accelerate BellaSeno´s market entry Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...

New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe New clinical trial site opened in Italy for pectus excavatum and planned in Germany for bone reconstructionCompany aims to expand EU market authorization from custom-made to off-the-shelf products and...

BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds Market entry under new EU regulations for medical devicesSpearheading the commercialization of 3D-printed regenerative medicine products Leipzig, Germany, July 6, 2023 – BellaSeno GmbH, an ISO...

BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction Data presented at the 24th EFFORT Congress in Vienna (Austria) Leipzig, Germany, June 20, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using...